KLDO (Kaleido Biosciences) EBITDA Margin %: -3,852.24% (As of Dec. 2021)


What is Kaleido Biosciences EBITDA Margin %?

Kaleido Biosciences KLDO EBITDA Margin % is -3,852.24% as of Dec. 2021.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kaleido Biosciences's EBITDA for the three months ended in Dec. 2021 was $-18.95 Mil. Kaleido Biosciences's Revenue for the three months ended in Dec. 2021 was $0.49 Mil. Therefore, Kaleido Biosciences's EBITDA margin for the quarter that ended in Dec. 2021 was -3,852.24%.

Kaleido Biosciences  (OTCPK:KLDO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Kaleido Biosciences EBITDA Margin % Related Terms

Kaleido Biosciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Kaleido Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences EBITDA Margin % Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 -7,896.92 -7,707.61

Kaleido Biosciences Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7,709.88 -7,325.25 -10,711.37 -20,944.23 -3,852.24

KLDO vs NPTX, GSTC, BZYR: EBITDA Margin % Comparison

For the Biotechnology subindustry, Kaleido Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kaleido Biosciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kaleido Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Kaleido Biosciences's EBITDA Margin % falls into.


Kaleido Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Kaleido Biosciences's EBITDA Margin % for the fiscal year that ended in Dec. 2021 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-85.092/1.104
=-7,707.61 %

Kaleido Biosciences's EBITDA Margin % for the quarter that ended in Dec. 2021 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2021 )/Revenue (Q: Dec. 2021 )
=-18.953/0.492
=-3,852.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -3,852.24% mean?
Kaleido Biosciences (KLDO) has a EBITDA Margin % of -3,852.24% as of Dec. 2021. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kaleido Biosciences and its competitors.
Is Kaleido Biosciences' EBITDA Margin % too high?
Kaleido Biosciences' current EBITDA Margin % is -3,852.24%.
How does Kaleido Biosciences' EBITDA Margin % compare to NPTX and GSTC?
Kaleido Biosciences' EBITDA Margin % of -3,852.24% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kaleido Biosciences and its competitors. Kaleido Biosciences's current EBITDA Margin % is -3,852.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current EBITDA Margin % of -3,852.24%. The current EBITDA Margin % is -3,852.24%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current EBITDA Margin % is -3,852.24% as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaleido Biosciences Business Description

Address 65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.